Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure

European Journal of Heart Failure

Volumn 5, Issue 2, 2003, Pages 147-154

  Gschwend, Simone ^a   Buikema, Hendrik ^a   Henning, Robert H ^a   Pinto, Yigal M ^b   De Zeeuw, Dick ^a   Van Gilst, Wiek H ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Coronary ligation induced chronic heart failure; EDHF; Endothelial dysfunction; Infarct size; Nitric oxide

Indexed keywords

ACETYLCHOLINE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENDOTHELIUM CELL; HEART FAILURE; HEART INFARCTION SIZE; HEMODYNAMICS; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL FACTORS; BLOOD PRESSURE; CARDIAC SURGICAL PROCEDURES; CHRONIC DISEASE; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; MALE; MODELS, CARDIOVASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; NITRIC OXIDE; ORGAN SIZE; RATS; RATS, WISTAR; VASODILATOR AGENTS; VENTRICULAR PRESSURE;

EID: 0037350543     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00248-9     Document Type: Article

References (41)

1. Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998;19:G48-G53.
2. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;19:577-85.
3. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res 1999;43:838-49.
4. Thorin E, Lucas M, Cernacek P, Dupuis J. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure. Am J Physiol Heart Circ Physiol 2000;279:H844-H851.
5. Mombouli J-V, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Moll Cell Cardiol 1999;31:61-74.
6. Drexler H, Hayoz D, Munzel T, Just H, Zelis R, Brunner HR. Endothelial function in congestive heart failure. Am Heart J 1993;126:761-4.
7. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-dependent vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992;19:918-25.
8. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
9. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991;69:1088-96.
10. Teerlink JR, Clozel M, Fischli W, Clozel JP. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. J Am Coll Cardiol 1993;22:615-20.
11. Mulder P, Elfertak L, Richard V, et al. Peripheral artery structure and endothelial function in heart failure: effect of ACE inhibition. Am J Physiol 1996;271:H469-H477.
12. Feletou M, Vanhoutte PM. Endothelial dysfunction: a novel Therapeutic Target; The Alternative: EDHF. J Moll Cell Cardiol 1999;31:15-22.
13. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-6.
14. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-23.
15. Randall MD, Alexander SP, Benett T, et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 1996;229:114-20.
16. + is an endothelium-derived hyperpolarizing factor in rats. Nature 1998;396:269-72.
17. 2. Circ Res 1999;84:53-63.
18. Malmsjö M, Bergdahl A, Zhao X-H, et al. Enhanced acetylcholine and P2Y-receptor stimulated vascular EDHF-dilatation in congestive heart failure. Cardiovasc Res 1999;43:200-9.
19. Nasa Y, Toyoshima H, Ohaku H, Hashizume Y, Sanbe A, Takeo S. Impairment of cGMP- and cAMP-mediated vasorelaxations in rats with chronic heart failure. Am J Physiol Heart Circ Physiol 1996;271:2228-37.
20. Teerlink JR, Gray GA, Clozel M, Clozel J-P. Increased vascular responsiveness to norepinephrine in rats with heart failure is endothelium-dependent. Circulation 1994;89:393-401.
21. Ikenaga H, Ishii N, Didion SP, et al. Suppressed impact of nitric oxide on renal arteriolar function in rats with chronic heart failure. Am J Physiol 1999;276:F79-F87.
22. Baggia S, Perkins K, Greenberg B. Endothelium-dependent relaxation is not uniformly impaired in chronic heart failure. J Cardiovasc Pharmacol 1997;29:389-96.
23. Thuillez C, Mulder P, Elfertak L, et al. Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure. Am J Hypertens 1995;8:7S-12S.
24. Drexler H, Lu W. Endothelial dysfunction of hind-quarter resistance vessels in experimental heart failure. Am J Physiol 1992;262:1640-5.
25. de Vries RJM, Anthonio R, van Veldhuisen DJ, Scholtens E, Buikema H, van Gilst WH. Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction. J Cardiovasc Pharmacol 1997;30:683-9.
26. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12.
27. Pinto YM, de Smet BG, van Gilst WH, et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-8.
28. van Gilst WH, van Veldhuisen DJ, Hegeman H, et al. Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril. J Cardiovasc Pharmacol 1994;24:171-4.
29. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17:787-94.
30. Corriu C, Feletou M, Canet E, Vanhoutte PM. Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea pig. Br J Pharmacol 1996;119:959-64.
31. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH. Comparison of zofenopril and lisinopril to study the role of sulfhydryl-groups in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000;130:1999-2007.
32. Pinto YM, van Wijngaarden J, van Gilst WH, de Graeff PA, Wesseling H. The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Res Cardiol 1991;86:165-72.
33. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
34. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998;39:89-105.
35. Popp R, Fleming I, Busse R. Pulsatile stretch in coronary arteries elicits release of endothelium-derived hyperpolarizing factor. A modulator of arterial compliance. Circ Res 1998;82:696-703.
36. Fisslthaler B, Popp R, Michaelis UR, Kiss L, Fleming I, Busse R. Cyclic stretch enhances the expression and activity of coronary endothelium-derived hyperpolarizing factor synthase. Hypertension 2001;38:1427-32.
37. Bloch W, Mehlhorn U, Krahwinkel A, et al. Ischemia increases detectable endothelial nitric oxide synthase in rat and human myocardium. Nitric Oxide 2001;5:317-33.
38. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999;100:292-8.
39. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998;31:189-93.
40. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997;29:235-41.
41. Baker JE, Konorev EA, Gross GJ, Chilian WM, Jacob HJ. Resistance to myocardial ischemia in five rat strains: is there a genetic component of cardioprotection? Am J Physiol Heart Circ Physiol 2000;278:1395-400.